Pre Seed · Biotech · Altrincham, United Kingdom · Founded 2025 · 5–5 employees
FinalDose is developing a programmable DNA‑activated therapeutic platform designed to target and destroy diseased cells by recognizing specific genetic sequences, potentially unlocking treatments for 80% of previously undruggable targets, starting with cancer. The company was founded in 2025 by Oxford PhD scientists and engineers and has already been accepted into Y Combinator’s Spring 2026 batch, a notable validation of its scientific and business model. It remains in stealth mode but has publicly announced its novel drug model that collapses R&D timelines and costs by reprogramming a single molecular payload. The founding team includes experienced researchers with track records in CRISPR screening and pandemic-scale genetic studies, lending both technical credibility and a foundation for rapid development.